WO2003087323A3 - Biologic modulations with nanoparticles - Google Patents

Biologic modulations with nanoparticles Download PDF

Info

Publication number
WO2003087323A3
WO2003087323A3 PCT/US2003/010850 US0310850W WO03087323A3 WO 2003087323 A3 WO2003087323 A3 WO 2003087323A3 US 0310850 W US0310850 W US 0310850W WO 03087323 A3 WO03087323 A3 WO 03087323A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell recognition
nanoparticles
alpha
modulations
biologic
Prior art date
Application number
PCT/US2003/010850
Other languages
French (fr)
Other versions
WO2003087323A2 (en
Inventor
Gretchen M Unger
Original Assignee
Genesegues Inc
Gretchen M Unger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesegues Inc, Gretchen M Unger filed Critical Genesegues Inc
Priority to EP03718282A priority Critical patent/EP1497442A2/en
Priority to AU2003221703A priority patent/AU2003221703A1/en
Publication of WO2003087323A2 publication Critical patent/WO2003087323A2/en
Publication of WO2003087323A3 publication Critical patent/WO2003087323A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use are also set forth, including the use of antisense directed against Protein Kinase CK2, CK2 alpha, CK2 alpha’, and CK2 beta.
PCT/US2003/010850 2002-04-08 2003-04-08 Biologic modulations with nanoparticles WO2003087323A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03718282A EP1497442A2 (en) 2002-04-08 2003-04-08 Biologic modulations with nanoparticles
AU2003221703A AU2003221703A1 (en) 2002-04-08 2003-04-08 Biologic modulations with nanoparticles

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US37088202P 2002-04-08 2002-04-08
US60/370,882 2002-04-08
US39431502P 2002-07-08 2002-07-08
US60/394,315 2002-07-08
US42829602P 2002-11-22 2002-11-22
US60/428,296 2002-11-22
US10/378,044 US20040038303A1 (en) 2002-04-08 2003-02-28 Biologic modulations with nanoparticles
US10/378,044 2003-02-28

Publications (2)

Publication Number Publication Date
WO2003087323A2 WO2003087323A2 (en) 2003-10-23
WO2003087323A3 true WO2003087323A3 (en) 2004-06-10

Family

ID=29255576

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2003/010854 WO2003087021A2 (en) 2002-04-08 2003-04-08 Nanoparticle delivery systems and methods of use thereof
PCT/US2003/010850 WO2003087323A2 (en) 2002-04-08 2003-04-08 Biologic modulations with nanoparticles
PCT/US2003/010729 WO2003087389A2 (en) 2002-04-08 2003-04-08 Biologic modulations with nanoparticles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010854 WO2003087021A2 (en) 2002-04-08 2003-04-08 Nanoparticle delivery systems and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010729 WO2003087389A2 (en) 2002-04-08 2003-04-08 Biologic modulations with nanoparticles

Country Status (4)

Country Link
US (6) US20040038303A1 (en)
EP (1) EP1497442A2 (en)
AU (3) AU2003231994A1 (en)
WO (3) WO2003087021A2 (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001247244B2 (en) * 2000-02-28 2005-06-02 Genesegues, Inc. Nanocapsule encapsulation system and method
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US9011880B2 (en) * 2003-10-21 2015-04-21 Igf Oncology, Llc Compounds and methods for treating cancer
JP4836798B2 (en) * 2003-10-21 2011-12-14 アイジーエフ オンコロジー エルエルシー Compounds and methods for treating cancer
US20050171424A1 (en) * 2004-01-13 2005-08-04 The Gov. Of The Usa As Rep. By The Secretary Of The Dept. Of Health And Human Services Methods for imaging the lymphatic system using dendrimer-based contrast agents
WO2005072292A2 (en) * 2004-01-24 2005-08-11 Hugh Mctavish Methods for enhancing radiation therapy
WO2006080951A2 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
FR2873386B1 (en) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa VACCINE COMPOSITION AGAINST RHODOCOCCUS EQUI
WO2006012695A1 (en) * 2004-08-04 2006-02-09 Panvax Limited An immunogenic composition
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
EP1812864A2 (en) * 2004-10-07 2007-08-01 Emory University Multifunctional nanoparticles conjugates and their use
WO2006047214A2 (en) 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
WO2006065894A2 (en) * 2004-12-14 2006-06-22 University Of South Florida Methods for inhibiting stat3 signaling in immune cells
WO2006065724A2 (en) * 2004-12-14 2006-06-22 Regents Of The University Of Minnesota Casein kinase 2 antisense therapy
WO2006075172A2 (en) * 2005-01-13 2006-07-20 University Of Dundee Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
US8066759B2 (en) * 2005-02-04 2011-11-29 Boston Scientific Scimed, Inc. Resonator for medical device
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
US8246995B2 (en) * 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US20060257355A1 (en) * 2005-05-10 2006-11-16 Abiomed, Inc. Impregnated polymer compositions and devices using them
US7595469B2 (en) * 2005-05-24 2009-09-29 Boston Scientific Scimed, Inc. Resonator for medical device
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
GB2441581B (en) * 2005-06-24 2011-01-19 Roderic M K Dale Compositions and methods for the treatment of muscle wasting
US7279664B2 (en) * 2005-07-26 2007-10-09 Boston Scientific Scimed, Inc. Resonator for medical device
US7304277B2 (en) * 2005-08-23 2007-12-04 Boston Scientific Scimed, Inc Resonator with adjustable capacitor for medical device
US7524282B2 (en) * 2005-08-29 2009-04-28 Boston Scientific Scimed, Inc. Cardiac sleeve apparatus, system and method of use
US7423496B2 (en) * 2005-11-09 2008-09-09 Boston Scientific Scimed, Inc. Resonator with adjustable capacitance for medical device
WO2007130873A2 (en) * 2006-04-28 2007-11-15 Regents Of The University Of Minnesota Liver-specific nanocapsules and methods of using
US8097596B2 (en) * 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
US20100015068A1 (en) * 2006-07-06 2010-01-21 Massachusetts Institute Of Technology Methods and Compositions For Altering Biological Surfaces
WO2008031035A2 (en) * 2006-09-08 2008-03-13 The Regents Of The University Of California Engineering shape of polymeric micro-and nanoparticles
WO2008091465A2 (en) * 2006-12-21 2008-07-31 Wayne State University Peg and targeting ligands on nanoparticle surface
MX2009008470A (en) 2007-02-09 2009-11-26 Univ Northwestern Particles for detecting intracellular targets.
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008115641A2 (en) 2007-02-15 2008-09-25 Yale University Modular nanoparticles for adaptable vaccines
DK2826863T3 (en) 2007-05-30 2017-12-04 Univ Northwestern NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS
US8535726B2 (en) * 2007-07-27 2013-09-17 The Board Of Trustees Of The Leland Stanford Junior University Supramolecular functionalization of graphitic nanoparticles for drug delivery
US20090062724A1 (en) * 2007-08-31 2009-03-05 Rixen Chen System and apparatus for sonodynamic therapy
CA2697629A1 (en) 2007-09-24 2009-04-02 The University Of Queensland Molecular delivery vesicle
EP2062592A1 (en) * 2007-11-20 2009-05-27 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten System for delivery into a XCR1 positive cell and uses thereof
WO2009108932A2 (en) * 2008-02-28 2009-09-03 The Johns Hopkins University Selectin ligands useful in the diagnosis and treatment of cancer
CN101658533A (en) * 2008-08-29 2010-03-03 首都医科大学宣武医院 Delivery of stem cells of antitumor medicament
US9233137B2 (en) 2008-11-07 2016-01-12 Celdara Medical, Llc Dendritic cell modulation in post-ischemic wounds
KR101692880B1 (en) 2008-11-24 2017-01-04 노오쓰웨스턴 유니버시티 Polyvalent rna-nanoparticle compositions
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
JP6145270B2 (en) * 2009-04-15 2017-06-07 ノースウェスタン ユニバーシティ Delivery of oligonucleotide functionalized nanoparticles
WO2010123569A2 (en) * 2009-04-21 2010-10-28 Selecta Biosciences, Inc. Immunonanotherapeutics providing a th1-biased response
EP2435094A2 (en) 2009-05-27 2012-04-04 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
EP2494075B1 (en) 2009-10-30 2018-04-04 Northwestern University Templated nanoconjugates
US8461300B2 (en) * 2010-03-22 2013-06-11 Sandia Corporation Materials and methods for stabilizing nanoparticles in salt solutions
US20120076735A1 (en) * 2010-03-24 2012-03-29 Genesegues, Inc. Nanoparticles for Extravascular Administration
US9650244B2 (en) 2010-08-25 2017-05-16 Genesegues, Inc. Topical vaccination via DNA microparticles
TWI458833B (en) * 2010-05-11 2014-11-01 Univ China Medical Nanometal dispersion and method for preparing the same
BR112012029912A2 (en) 2010-05-26 2016-11-16 Selecta Biosciences Inc Synthetic Nanotransport Combination Vaccines
US20120189677A1 (en) * 2011-01-20 2012-07-26 Stephen Tonge Formulations
ES2629187T3 (en) 2011-04-20 2017-08-07 The University Of Sydney Particle material and cellular toxin for use in the treatment of a solid tumor
EP2704715B1 (en) 2011-04-29 2020-04-01 Selecta Biosciences, Inc. Synthetic nanocarriers for generating cd8+regulatory t cells for use in inducing tolerogenesis
US8934698B2 (en) * 2011-06-22 2015-01-13 The Johns Hopkins University System and device for characterizing cells
WO2013019669A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
JP2014526517A (en) 2011-09-14 2014-10-06 ノースウェスタン ユニバーシティ Nanoconjugates that can cross the blood-brain barrier
WO2013123298A1 (en) 2012-02-17 2013-08-22 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2013125232A1 (en) * 2012-02-23 2013-08-29 キヤノン株式会社 Dye-containing nanoparticle for photoacoustic contrast agent
WO2013130619A1 (en) * 2012-02-27 2013-09-06 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
WO2013134777A1 (en) * 2012-03-09 2013-09-12 Northeastern University Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
KR102233251B1 (en) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 Novel nanoparticle compositions
US9138476B2 (en) * 2013-04-16 2015-09-22 Academia Sinica Nanoparticle-assisted ultrasound for cancer therapy
WO2014176389A1 (en) 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
CN105339012A (en) 2013-05-03 2016-02-17 西莱克塔生物科技公司 Local, concomitant administration of tolerogenic synthetic nanocarriers to reduce type i and type iv hypersensitivity
JP6835590B2 (en) 2014-01-12 2021-02-24 アイジーエフ オンコロジー、 エルエルシー Fusion proteins containing insulin-like growth factor-1 and epithelial growth factors and variants thereof and their use
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
TR201908550T4 (en) 2014-06-04 2019-07-22 Exicure Inc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications.
KR20170054429A (en) 2014-09-03 2017-05-17 제네세규스 인코포레이티드 Therapeutic nanoparticles and related compositions, methods, and systems
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
JP7218089B2 (en) * 2014-11-05 2023-02-06 セレクタ バイオサイエンシーズ インコーポレーテッド Methods and compositions relating to synthetic nanocarriers with rapamycin in a stable supersaturated state
JP2017537619A (en) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
EP3592389A1 (en) 2017-03-11 2020-01-15 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US10543231B2 (en) 2017-05-19 2020-01-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3630195A4 (en) 2017-05-21 2021-03-24 IGF Oncology, LLC An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
JP7119331B2 (en) * 2017-10-13 2022-08-17 富士通株式会社 Transmission system and transmission method
KR20200138234A (en) 2018-02-28 2020-12-09 유니버시티 오브 워싱톤 Self-assembled nanostructured vaccine
CA3197971A1 (en) 2020-11-13 2022-05-19 Andrew Lawrence Feldhaus Protein-based nanoparticle vaccine for metapneumovirus
WO2023225562A1 (en) 2022-05-17 2023-11-23 Icosavax, Inc. Multivalent vaccine for paramyxoviruses and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962566A (en) * 1995-07-05 1999-10-05 European Community Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery
WO2001064164A2 (en) * 2000-02-28 2001-09-07 Genesegues, Inc. Nanocapsule encapsulation system and method

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4356270A (en) * 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4332901A (en) * 1978-02-27 1982-06-01 President And Fellows Of Harvard College Cloning vector
US4336336A (en) * 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
US4273875A (en) * 1979-03-05 1981-06-16 The Upjohn Company Plasmid and process of isolating same
AU542264B2 (en) * 1979-06-01 1985-02-14 G.D. Searle & Co. Plasmid vectors
US4403036A (en) * 1980-12-02 1983-09-06 University Of Iowa Research Foundation Genetic reagents for generating plasmids containing multiple copies of DNA segments
FR2504408B1 (en) * 1981-04-24 1986-02-14 Couvreur Patrick PROCESS FOR THE PREPARATION OF SUBMICROSCOPIC PARTICLES, PARTICLES THUS OBTAINED AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5188816A (en) * 1984-10-18 1993-02-23 Board Of Regents, The University Of Texas System Using polyazamacrocyclic compounds for intracellular measurement of metal ions using MRS
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
ATE81872T1 (en) * 1985-03-15 1992-11-15 James Summerton STEROREOGULAR POLYNUCLEOTIDE BINDING POLYMERS.
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5219553A (en) * 1986-08-04 1993-06-15 Salutar, Inc. Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI
ES2053549T3 (en) * 1986-08-11 1994-08-01 Innovata Biomed Ltd A PROCESS FOR THE PREPARATION OF AN APPROPRIATE PHARMACEUTICAL FORMULATION FOR INHALATION.
DE3788914T2 (en) * 1986-09-08 1994-08-25 Ajinomoto Kk Compounds for cleaving RNA at a specific position, oligomers used in the preparation of these compounds and starting materials for the synthesis of these oligomers.
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
FR2634397B2 (en) * 1986-12-31 1991-04-19 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF DISPERSIBLE COLLOIDAL SYSTEMS OF A PROTEIN IN THE FORM OF NANOPARTICLES
AU610594B2 (en) * 1987-04-16 1991-05-23 Christian Bindschaedler Process for preparing a powder of water-insoluble polymer which can be redispersed in a liquid phase, the resulting powder and utilization thereof
US5827821A (en) * 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
US4937119A (en) * 1988-12-15 1990-06-26 Hoechst Celanese Corp. Textured organic optical data storage media and methods of preparation
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
GB2234234B (en) * 1989-07-19 1992-08-12 British Gas Plc Treatment for reducing impurities in aqueous liquor
US5872231A (en) * 1990-01-30 1999-02-16 La Jolla Cancer Research Foundation Nucleic acids encoding merosin
IL98744A0 (en) * 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6287792B1 (en) * 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
CA2082411A1 (en) * 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5500013A (en) * 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US6235313B1 (en) * 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
EP0567394A3 (en) * 1992-04-24 1995-04-26 Fujikura Ltd Cable termination assembly.
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
DE4223169C1 (en) * 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Process for the microencapsulation of water-soluble active substances
WO1994003601A2 (en) * 1992-08-03 1994-02-17 New York University Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
WO1994018954A1 (en) * 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
ES2215207T3 (en) * 1993-03-09 2004-10-01 Baxter International Inc. MACROMOLECULES MICROPARTICLES AND PRODUCTION METHODS.
FR2704754B1 (en) * 1993-05-07 1995-06-30 Oreal USE OF AN ALKYL ESTER OF GLUTATHION IN A COSMETIC OR DERMATOLOGICAL COMPOSITION FOR TOPICAL TREATMENT OF CUTANEOUS AGING.
US5646248A (en) * 1993-06-08 1997-07-08 La Jolla Cancer Research Foundation E-selection binding soluble lamp-1 polypeptide
DK1155689T3 (en) * 1993-07-19 2006-11-20 Angiotech Pharm Inc Antiangiogenic stents and methods for their preparation
AU7208494A (en) * 1993-07-28 1995-02-28 Johns Hopkins University School Of Medicine, The Controlled release of pharmaceutically active substances from coacervate microcapsules
US5358704A (en) * 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
US5610031A (en) * 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US5885211A (en) * 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
CA2136373A1 (en) * 1993-11-29 1995-05-30 Steven W. Medina Ethoxylated acetylenic glycols having low dynamic surface tension
US5625040A (en) * 1994-01-27 1997-04-29 The Research Foundation Of State University Of New York Phosphacan: a chondroitin sulfate proteoglycan of brain that interacts with neurons and neural cell adhesion molecules
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
FR2721510B1 (en) * 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticles filterable under sterile conditions.
US5891108A (en) * 1994-09-12 1999-04-06 Cordis Corporation Drug delivery stent
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US5766922A (en) * 1995-05-26 1998-06-16 Sugen, Inc. Functional ligands for the axonal cell rcognition molecule contactin
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US6051258A (en) * 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6041252A (en) * 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6350780B1 (en) * 1995-07-28 2002-02-26 Allergan Sales, Inc. Methods and compositions for drug delivery
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
DE69636074T2 (en) * 1995-09-08 2007-05-03 Beth Israel Deaconess Medical Center, Boston INSULATION OF MICRODOMANS OF KAVEOLAE AND GPI ANCHORED PROTEINS
KR19990063632A (en) * 1995-09-21 1999-07-26 디 헤이쓰, 산드라 우드 Transcytosis Mediators and Synergists for Drug Transport
US5648097A (en) * 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
FR2742357B1 (en) * 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa STABILIZED AND FILTRABLE NANOPARTICLES UNDER STERILE CONDITIONS
DE19605279A1 (en) * 1996-02-13 1997-08-14 Hoechst Ag Target cell-specific vectors for the introduction of genes into cells, drugs containing such vectors and their use
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US6074673A (en) * 1996-04-22 2000-06-13 Guillen; Manuel Slow-release, self-absorbing, drug delivery system
US6074609A (en) * 1996-04-24 2000-06-13 Glaxo Wellcome Inc. Systems for arraying beads
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6491903B1 (en) * 1996-06-27 2002-12-10 Washington University Particles comprising amphiphilic copolymers
US6140117A (en) * 1996-07-24 2000-10-31 Washington University Ninjurin
US5945100A (en) * 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6030956A (en) * 1996-10-24 2000-02-29 Boulikas; Teni Combination gene therapy for human cancers
WO1998018452A1 (en) * 1996-10-25 1998-05-07 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
ZA9710342B (en) * 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US6121231A (en) * 1996-12-06 2000-09-19 Institut Pasteur Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuromal and neural injury
AU5901598A (en) * 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
US5874111A (en) * 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US5866165A (en) * 1997-01-15 1999-02-02 Orquest, Inc. Collagen-polysaccharide matrix for bone and cartilage repair
US6416778B1 (en) * 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6086582A (en) * 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
US6404705B1 (en) * 1997-03-14 2002-06-11 Hitachi Maxell, Ltd. Magneto-optical disk apparatus having an adjustment mechanism for setting the position of magnetic heads
CA2286177C (en) * 1997-04-07 2011-06-21 Daiichi Pharmaceutical Co., Ltd. Composition for gene transfer into cells
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
EP0895149B1 (en) * 1997-07-31 2003-09-17 Siemens Aktiengesellschaft Computer system for protecting a file and a method for protecting a file
ZA988461B (en) * 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
AU749625B2 (en) * 1998-01-16 2002-06-27 Johns Hopkins University, The Oral delivery of nucleic acid vaccines by particulate complexes
US6086912A (en) * 1998-02-11 2000-07-11 Gilman; Marvin S. Topical drug delivery system
US6303114B1 (en) * 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6232287B1 (en) * 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6395253B2 (en) * 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
US6174867B1 (en) * 1998-05-08 2001-01-16 Synsorb Biotech, Inc. 1-galactose derivatives having a carbon- or nitrogen-containing aglycon linkage
IL140276A0 (en) * 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
US6326144B1 (en) * 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
US6251303B1 (en) * 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6251079B1 (en) * 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
US6124260A (en) * 1998-09-30 2000-09-26 Cedars-Sinai Medical Center Inhibition of smooth muscle cell migration by Tenascin-C peptides
US7052834B1 (en) * 1998-12-31 2006-05-30 St. Jude Children's Research Hospital Tumor suppressor protein involved in death signaling, and diagnostics, therapeutics, and screening based on this protein
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6528481B1 (en) * 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6283947B1 (en) * 1999-07-13 2001-09-04 Advanced Cardiovascular Systems, Inc. Local drug delivery injection catheter
WO2001041760A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US6283949B1 (en) * 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US6379382B1 (en) * 2000-03-13 2002-04-30 Jun Yang Stent having cover with drug delivery capability
US6440738B1 (en) * 2001-02-08 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of casein kinase 2-beta expression
US6607916B2 (en) * 2001-02-08 2003-08-19 Isis Pharmaceuticals, Inc. Antisense inhibition of Casein kinase 2-alpha expression
US6455307B1 (en) * 2001-02-08 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of casein kinase 2-alpha prime expression
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US6797685B2 (en) * 2002-04-26 2004-09-28 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Liquid laundry detergent with emulsion layer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962566A (en) * 1995-07-05 1999-10-05 European Community Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery
WO2001064164A2 (en) * 2000-02-28 2001-09-07 Genesegues, Inc. Nanocapsule encapsulation system and method

Also Published As

Publication number Publication date
AU2003231994A8 (en) 2003-10-27
WO2003087323A2 (en) 2003-10-23
WO2003087021A3 (en) 2004-04-08
WO2003087021A2 (en) 2003-10-23
US20080220072A1 (en) 2008-09-11
WO2003087389A3 (en) 2005-04-28
US20100247662A1 (en) 2010-09-30
AU2003221703A8 (en) 2003-10-27
WO2003087389A2 (en) 2003-10-23
US20070098713A1 (en) 2007-05-03
US20060018826A1 (en) 2006-01-26
EP1497442A2 (en) 2005-01-19
AU2003224876A8 (en) 2003-10-27
US20040038406A1 (en) 2004-02-26
US20040038303A1 (en) 2004-02-26
WO2003087021A8 (en) 2004-11-18
AU2003224876A1 (en) 2003-10-27
AU2003221703A1 (en) 2003-10-27
AU2003231994A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
WO2003087323A3 (en) Biologic modulations with nanoparticles
Kao et al. In vivo modulation of host response and macrophage behavior by polymer networks grafted with fibronectin-derived biomimetic oligopeptides: the role of RGD and PHSRN domains
KR101692911B1 (en) Minimally Invasive Treatment of Vertebra(MITV) Using a Calcium Phosphate Combination Bone Cement
Sakiyama-Elbert et al. Functional biomaterials: design of novel biomaterials
AU9036598A (en) Methods and compositions to prevent formation of adhesions in biological tissues
Gebelein et al. Biomedical and dental applications of polymers
WO2005032511A3 (en) Nanoparticulate therapeutic biologically active agents
MXPA05007146A (en) Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles.
WO2003000014A3 (en) Spherical protein particles and methods of making and using them
JP2017500960A (en) Functional lubricating medical device coating
EP2671540A3 (en) Progenitor endothelial cell capturing with a drug eluting implantable medical device
BR0313539A (en) Injectable multimodal polymer deposit compositions and their uses
DE59908745D1 (en) PHARMACEUTICAL CICLOSPORIN FORMULATION WITH IMPROVED BIOPHARMACEUTICAL PROPERTIES, INCREASED PHYSICAL QUALITY & STABILITY AND METHOD FOR THE PRODUCTION THEREOF
HU223880B1 (en) Gel formulations containing growth factors
WO2005099621A3 (en) Topographic coatings and coating methods for medical devices
EP2037851A2 (en) Coating of devices with effector compounds
ATE307620T1 (en) IMPLANT MATERIAL WITH GLASS PARTICLES
MXPA05007928A (en) Disposable absorbent article comprising a durable hydrophilic topsheet.
NO20061899L (en) Artificial biological implant and its use and method for reducing the risk of connective tissue formation after implantation
WO2002080881A3 (en) Process for making protein delivery matrix and uses thereof
He et al. Impact of biomaterials’ physical properties on cellular and molecular responses
Gao et al. Enhanced Retention of rhBMP‐2 In Vivo by Thermoreversible Polymers
RU2005129620A (en) CONJUGATE POSSESSING THE ELECTIVE ACTION FOR CANCER TUMORS
BRPI0409424A (en) pharmaceutical composition for parenteral administration, method of treating a patient suffering from hemophilia, use of a colloidal particle, and method of treating a patient suffering from a disease
IL128329A0 (en) Pharmaceutical composition of hedgehog proteins and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003718282

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003718282

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP